# Progress Note 06 — Preventive Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Gwen Ifill (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML032-SYN-TD
- Date: 2016-08-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lorna Achebe-Price, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Preventive Visit
- Services: CPT 99396 (periodic preventive medicine, established patient, age 40 to 64) with CPT 99497 (advance care planning), both on the same day

## Chief complaint

Periodic adult preventive visit. **S**

## History of present illness

Ms. Ifill is a 60-year-old journalist with stage IIIC2 mismatch repair deficient endometrial cancer, treated with surgery and six cycles of dostarlimab, carboplatin and paclitaxel, who comes for her yearly preventive visit six weeks after the end of combination treatment. The CT then showed no evidence of disease. She had her first maintenance dose of dostarlimab six weeks ago and has her second today. Since starting levothyroxine her energy has improved and she no longer feels cold. The tingling in her toes is slowly fading. She has had no vaginal bleeding or discharge, pelvic pain, cough, leg swelling or weight loss. She is working full days again, covering the election campaign, and walks most mornings. **S**

| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 60 |
| Endometrial cancer | No evidence of disease at the end of treatment; dostarlimab maintenance dose 2 today |
| Thyroid | Levothyroxine for six weeks; energy better |
| Mood | PHQ-2 0 |

## Health risk assessment

Completed by the patient on the clinic's online form before the visit and reviewed with her by Dr. Achebe-Price. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Good, and improving |
| Psychosocial | Busy and engaged at work; close friends and church community; low stress apart from the campaign schedule |
| Substance use | No tobacco; alcohol occasionally, within low-risk limits; no drug use |
| Physical activity | Brisk walk of 30 minutes on most mornings |
| Nutrition | Regular meals; trying to eat more vegetables and less takeout on long workdays |
| Sleep | Six to seven hours on work nights |
| Falls and home safety | No falls; numbness in the toes is fading; good lighting at home |
| Sexual health | Not sexually active at present; knows to report vaginal dryness or pain |
| Activities of daily living | Independent |
| Seat belt and smoke alarms | Always wears a seat belt; smoke alarms tested |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy improving; no fever or weight loss |
| Eyes | Negative | No vision change |
| Ears, nose, mouth, and throat | Negative | No mouth sores |
| Cardiovascular | Negative | No chest pain, palpitations or leg swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | No diarrhea, abdominal pain or blood in the stool |
| Genitourinary | Negative | No vaginal bleeding or discharge; no urinary symptoms |
| Breast | Negative | No lump or nipple change |
| Musculoskeletal | Negative | No joint pain or swelling |
| Integumentary | Negative | No rash or itching |
| Neurological | Positive | Faint tingling in the toes, fading |
| Endocrine | Negative | No longer feels cold; no thirst |
| Psychiatric | Negative | Mood good; PHQ-2 0 |

13 systems reviewed. **S**

## Current medications

- Dostarlimab 50 mg/mL injection, 1000 mg intravenously over 30 minutes every 6 weeks as maintenance, for up to three years **S**
- Levothyroxine 75 mcg oral tablet, one tablet daily before breakfast **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/78 mmHg; pulse 70 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 73 kg; BMI 26.8 kg/m². All vital signs are synthetic.

TSH: 3.6 mIU/L; Free T4: 1.2 ng/dL; ALT: 21 U/L; Glucose: 93 mg/dL; Total cholesterol: 204 mg/dL (high); LDL cholesterol: 124 mg/dL; HDL cholesterol: 58 mg/dL; Triglycerides: 110 mg/dL; PHQ-2: 0. All results are synthetic.

## Change since baseline

- Glucose: 94 mg/dL at baseline, 93 mg/dL at this visit **S**
- PHQ-2: 1 at baseline, 0 at this visit **S**

## Immunizations given today

- Pneumococcal conjugate vaccine PCV20 **S**
- Recombinant zoster vaccine, dose 1 of 2 **S**
- Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Well; weight 73.0 kg; blood pressure 124/78; pulse 70 |
| Neck | Thyroid not enlarged or tender; no lymph nodes |
| Breasts | Clinical breast examination with a chaperone, at her choice: no masses, skin or nipple changes, or axillary nodes |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear |
| Abdomen | Port-site scars healed; soft, non-tender; no mass |
| Lymph nodes | No inguinal or supraclavicular nodes |
| Extremities | No leg swelling; calf circumferences equal |
| Skin | No rash or suspicious lesions |
| Neurological | Pinprick slightly reduced over the toes only; vibration and ankle reflexes normal; steady gait |
| Psychiatric | Engaged and direct |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Periodic adult preventive visit completed**. Health risk assessment reviewed and the prevention plan updated. Mammogram ordered: screening every two years from 40 to 74. Cervical screening is no longer indicated after total hysterectomy, and vaginal cytology is not used to look for recurrence. Colorectal screening is due: the cancer's mismatch repair loss was acquired, so average-risk screening applies, and she chose a stool immunochemical test. Lipids: total cholesterol 204, LDL 124, HDL 58 mg/dL; ten-year risk estimated as below the statin threshold, with lifestyle advice. A1c 5.5% earlier this year. **S**
   - Mammogram in two weeks.
   - Stool immunochemical test kit given today.
   - Influenza and COVID-19 vaccines this autumn.
   - Second zoster dose in two to six months.
   - Bone density at 65, sooner if a fracture or new risk factor.
   - Next preventive visit in one year.
2. **Endometrioid endometrial cancer, FIGO stage IIIC2ii, MMRd, no evidence of disease** (C54.1). No symptom or sign of recurrence. ALT 21 U/L and glucose 93 mg/dL before the second maintenance dose of dostarlimab, given today in the infusion center. **S**
   - Dostarlimab 1000 mg every six weeks.
   - Gynecologic oncology examination every three months; CT every six months for three years.
3. **Immune-related hypothyroidism on dostarlimab** (E03.2). TSH 3.6 and free T4 1.2 on levothyroxine 75 mcg; symptoms resolved. **S**
   - Continue levothyroxine 75 mcg daily.
   - TSH and free T4 every six weeks with the dostarlimab doses.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 124/78 mmHg |
| Depression screening | Completed today | PHQ-2 score 0; PHQ-9 4 six weeks ago |
| Unhealthy alcohol use screening | Completed today | Occasional use within low-risk limits |
| Tobacco use | Completed today | Never |
| Breast cancer screening | Ordered | Mammogram every two years from 40 to 74; none in the past two years on file; booked in two weeks |
| Cervical cancer screening | Not indicated | Total hysterectomy with removal of the cervix for endometrial cancer; routine vaginal cytology is not recommended for surveillance |
| Colorectal cancer screening | Ordered | No screening on file; the tumor's MLH1 loss is explained by promoter methylation, so average-risk screening applies; stool immunochemical test chosen, with colonoscopy if positive |
| Diabetes and lipid screening | Completed today | A1c 5.5% at intake; total cholesterol 204, LDL 124, HDL 58, triglycerides 110 mg/dL; ten-year risk below the statin threshold |
| HIV and hepatitis C screening | Up to date | Both negative before cancer treatment |
| Osteoporosis screening | Not indicated | Age 60 without a fracture, steroid course or low body weight; bone density at 65 |
| Lung cancer screening | Not indicated | Never smoker |
| Pneumococcal, zoster and Tdap vaccines | Completed today | PCV20, recombinant zoster dose 1 and Tdap given today |
| Influenza and COVID-19 vaccines, this season | Due | This autumn, when the season's vaccines arrive |
| Dental and eye examinations | Due | Dental review and an eye examination advised this year |

## Advance care planning

Voluntary advance care planning discussion of about 20 minutes, with her consent. She wants full treatment aimed at cure and control of her cancer, wants to be told plainly what is happening, and wants to make her own decisions. She named a health care agent, recorded in the confidential part of the chart and not named here, and asked that information about her health be shared only with the people she names. She chose not to record other treatment preferences today. To be revisited yearly or if her illness changes. **S**

## Guideline basis

- Salani R, et al. Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statement. Gynecol Oncol 2026;204:109-117 (PMID 41308226) (2026), Society of Gynecologic Oncology
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force
- Breast Cancer: Screening (2024), U.S. Preventive Services Task Force
- Cervical Cancer: Screening (2018), U.S. Preventive Services Task Force
- Colorectal Cancer: Screening (2021), U.S. Preventive Services Task Force
- Osteoporosis to Prevent Fractures: Screening (2025), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Mammogram in two weeks; stool test result by phone. Dostarlimab every six weeks with TSH, free T4, liver tests and glucose. Gynecologic oncology examination every three months and CT every six months. Influenza and COVID-19 vaccines this autumn. Next preventive visit in one year. **S**

